News | January 30, 2009

Invatec, Lumen Biomedical Partner in Worldwide Distribution Agreement for Embolic Protection Devices

January 30, 2009 – Invatec this week announced it entered a worldwide distribution agreement with Lumen Biomedical Inc. to distribute the FiberNet Embolic Protection System (EPS), which received FDA clearance in November and CE Mark for use during carotid and saphenous vein graft procedures.

When the carotid arteries are obstructed, patients are at an increased risk for stroke, the third leading cause of death in the U.S. The FiberNet EPS captures debris released during the stenting procedure and prevents it from traveling to the brain, where it has the potential to cause a stroke.

The FiberNet system features a three-dimensional design composed of a matrix of fibers that entrap smaller particles and better overall capture efficiency compared to the currently available distal protection filters. The low-profile filter is mounted on a guidewire, needing no delivery system to cross the lesion. The FiberNet EPS will treat vessels ranging from 3.5 to 7 mm and its unique design ensures excellent wall apposition. After the particles have been captured, the FiberNet filter is retrieved into the retrieval catheter under aspiration and removed from the patient.

The FiberNet EPS was evaluated in the EPIC (Evaluating the Use of the FiberNet EPS in Carotid Artery Stenting) multicenter trial, which demonstrated the lowest stroke rates of any filter currently available in the U.S. market. As part of the trial, 237 high-surgical-risk patients with a critical carotid artery stenosis received carotid artery stenting. Overall, the 30-day stroke rate was 2.1 percent. There were no unanticipated adverse device effects. Visible debris was observed in over ninety percent of the procedures.

“The FiberNet EPS has several attributes including ease of use, low profile and the ability to conform to an irregular surface in the vessel wall, that have contributed to the impressive results and safety profile we observed in the EPIC trial,” said Dr. Subbarao Myla, medical director of cardiovascular research and endovascular intervention at Hoag Memorial Hospital in California and national principle investigator for the trial. “The device achieved the lowest stroke rate of any filter currently available, making FiberNet a top choice for physicians, and represents the next generation in embolic protection.”

Invatec’s carotid portfolio consists of the Mo.Ma Proximal Protection Device and the Cristallo Ideale Carotid Stent System, both of which have received CE Marks. In the U.S., Invatec currently has a pivotal investigational device exemption clinical trial called ARMOUR underway to assess the safety and efficacy of the Mo.Ma Proximal Protection Device for use in carotid stenting with FDA approved carotid stents.

For more information:

Related Content

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices| October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices| October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Overlay Init